ABSTRACT
The diagnosis of multiple myeloma requires detection of paraproteinemia and confirmation of monoclonal bone marrow infiltration, along with signs of end-organ damage. Despite the increasing prevalence, serum paraproteinemia is not routinely measured. We examined the relationship between alterations in routine hematological parameters and the development of paraproteinemia in a case-control study. Data was retrieved from a laboratory database in the capital region of Denmark between 01/01/2012 and 31/12/2022. Patients were included if they had a test for paraproteinemia (n = 134,740) and at least one prior hematological parameter (white blood cells, hemoglobin and platelet count) with a minimum follow-up of 1 year.Between 96,999 and 103,590 patients were included in each of the three hematological groups. We found white blood cell count and the presence of paraproteinemia followed an inverse J-shaped curve, with the highest presence below 3 × 109/L and above > 9 × 109/L. The adjusted OR below and above the nadir of 4 × 109/L was 1.61 (95% CI 1.25; 2.08, p < 0.0001) and 1.03 (95% CI 1.03; 1.04, p < 0.0001). Hemoglobin levels were inversely associated the presence of paraproteinemia, with the highest association below 6 mmol/L with an OR of 1.30 (95% CI 1.28; 1.32, p < 0.0001) adjusted for age and gender. Platelet count followed a U-shaped curve with the highest association at < 100 × 109/L. The adjusted OR below and above the nadir of 250 × 109/L was 1.13 (95% CI 1.10; 1.17, p < 0.0001) and 1.10 (95% CI 1.08; 1.12, p < 0.0001) respectively. In conclusion, all three parameters showed significant association with later paraproteinemia.
Subject(s)
Paraproteinemias , Humans , Male , Female , Case-Control Studies , Middle Aged , Aged , Paraproteinemias/blood , Aged, 80 and over , Multiple Myeloma/blood , Multiple Myeloma/epidemiology , Multiple Myeloma/diagnosis , Denmark/epidemiology , Adult , Platelet Count , Leukocyte Count , Hemoglobins/analysisSubject(s)
Paraproteins , Humans , Paraproteins/analysis , Paraproteinemias/blood , Paraproteinemias/diagnosisSubject(s)
Paraproteins , Humans , Paraproteins/analysis , Paraproteinemias/blood , Paraproteinemias/diagnosisSubject(s)
Paraproteins , Humans , Paraproteins/analysis , Male , Paraproteinemias/blood , Paraproteinemias/diagnosis , FemaleABSTRACT
Current guidelines recommend screening with serum M-protein and serum-free light chain analysis (S-FLC) when an M-protein-related disorder is suspected. Many patients with multiple myeloma will be overlooked if only serum M-protein is measured. Despite this, the general practitioners in some areas of Denmark cannot order S-FLC. This review aims to disseminate knowledge of the S-FLC analysis, its applicability, and limitations in the diagnostic workup for suspected monoclonal gammopathies.
Subject(s)
Immunoglobulin Light Chains , Multiple Myeloma , Humans , Immunoglobulin Light Chains/blood , Multiple Myeloma/diagnosis , Multiple Myeloma/blood , Paraproteinemias/diagnosis , Paraproteinemias/blood , Myeloma Proteins/analysisABSTRACT
Flow cytometry plays an important role in the diagnosis and treatment of plasma cell diseases, particularly in the detection of circulating plasma cells (CPCs) in the peripheral blood. A consensus about the normalized use of flow cytometry in detection of CPCs in peripheral blood in clinical practice has been achieved. This consensus is founded on evidence-based principles, which elucidates the timing and value of flow cytometry for the detection of CPCs in the monoclonal gammopathy of undetermined significance, smoldering myeloma, multiple myeloma, and plasma cell leukemia and standardizes flow cytometry in the detection of CPCs in plasma cell diseases.
Subject(s)
Flow Cytometry , Multiple Myeloma , Plasma Cells , Flow Cytometry/methods , Humans , Multiple Myeloma/diagnosis , Multiple Myeloma/blood , China , Paraproteinemias/diagnosis , Paraproteinemias/blood , Monoclonal Gammopathy of Undetermined Significance/diagnosis , Monoclonal Gammopathy of Undetermined Significance/blood , Consensus , East Asian PeopleABSTRACT
ABSTRACT: Plasma cell myeloma (PCM) is a monoclonal gammopathy (MGM) characterized by proliferation of abnormal clone of plasma cells infiltrating the bone marrow with consequent end organ damage. The clonal plasma cells secrete a single clone of immunoglobulins (Ig) leading to presence of M-protein in the serum and/or urine. The M-protein is appreciated as a discrete band on serum protein electrophoresis (SPE) in the gamma globulin region, also called the M-band. Biclonal gammopathy (BGM) occurs due to neoplastic transformation of a plasma cell clone undergoing Ig class switching or due to an independent neoplastic transformation event yielding proliferation of unrelated plasma cell clones, therefore resulting in two distinct M-bands on SPE. It is, however, vital to distinguish a true BGM from an apparent one (MGM presenting with two distinct bands on SPE) so as to make an accurate diagnosis. Hereby, we report a case of a 61-year-old man, diagnosed with PCM and presenting with two discrete bands on SPE (simulating a BGM) which turned out to be monoclonal in nature.
Subject(s)
Multiple Myeloma , Humans , Multiple Myeloma/diagnosis , Multiple Myeloma/blood , Multiple Myeloma/pathology , Male , Middle Aged , Blood Protein Electrophoresis/methods , Plasma Cells/pathology , Plasma Cells/metabolism , Myeloma Proteins/analysis , Diagnosis, Differential , Paraproteinemias/diagnosis , Paraproteinemias/bloodABSTRACT
BACKGROUND: Upon infection activated plasma cells produce large quantities of antibodies which can lead to the emergence of a monoclonal component (MC), detectable by serum protein electrophoresis (SPEP). This study aims to investigate any correlation between SARS-CoV-2 infection and MC development and, if identified, whether it persists during follow-up. METHODS: SPEPs of 786 patients admitted to hospitals between March 01 2020 and March 31 2022 were evaluated. Positive (SARS-CoV-2+) and negative (SARS-CoV-2-) patients to nasopharyngeal swab for SARS-CoV-2 by RT-PCR were included. The persistence/new occurrence of MC was investigated for all patients during follow-up. Patient groups were compared by chi-square analysis. RESULTS: MC was identified in 12% of all patients admitted to hospital, of which 28.7% were SARS-CoV-2+. The most common immunoglobulin isotype in both groups was IgG-k. There was no correlation between MC development and SARS-CoV-2 infection (p = 0.173). Furthermore, the risk of MC persistence in SARS-CoV-2-negative patients was revealed to be higher than in the SARS-CoV-2+ at follow-up (HR = 0.591, p = 0.05). CONCLUSIONS: Our study suggests that the detection of MC during SARS-CoV-2 infection is most likely due to the hyperstimulation of the humoral immune system, as also occurs in other viral infections.
Subject(s)
COVID-19 , Paraproteinemias , SARS-CoV-2 , Humans , COVID-19/immunology , COVID-19/blood , COVID-19/diagnosis , SARS-CoV-2/immunology , Male , Female , Middle Aged , Aged , Paraproteinemias/blood , Adult , Aged, 80 and over , Immunoglobulin G/blood , Immunoglobulin G/immunology , Blood Protein ElectrophoresisABSTRACT
Hematological neoplasms are tumors of cells in different states of maturation and differentiation. Since monoclonal gammopathies (MG) refer to B mature lymphocyte neoplasms, lymphogenesis should be well known. We must keep in mind that the last stage of maturation of these lymphocytes is the plasma cell. This is how a MG could appear in the context of a plasma cell neoplasm, such as multiple myeloma or amyloidosis, but also in relation to a lymphoma. A monoclonal peak is produced by mature B lymphocytes or plasma cells that secrete a monoclonal protein (Immunoglobulin), and represents a MG. But it must be emphasized that, in the correct clinical context, a hypogammaglobulinemia can represent a MG as well. Another important point is the understanding and interpretation of requested tests, such as protein electrophoresis (PEP), immunofixation (IFx) or serum free light chains (sFLC). The current MG screening panel includes these three studies (PEF, IFx, sFLC), although a simpler panel measuring PEF and sFLC has also been proposed, but not yet formally validated. Therefore, screening done only with PEP is insufficient.
Subject(s)
Humans , Paraproteinemias/blood , Paraproteins/analysis , Neoplasms, Plasma Cell/blood , Paraproteinemias/diagnosis , Blood Protein Electrophoresis/methods , B-Lymphocytes/metabolism , Neoplasms, Plasma Cell/diagnosisABSTRACT
Relatar um caso de depósito corneano de cobre em ambos os olhos a nível da membrana de Descemet associado a gamopatia monoclonal de significância indeterminada (GMSI). Paciente feminina, 49 anos, leucodérmica, apresentando depósito corneano de aspecto marrom-ouro a nível da membrana de Descemet em ambos os olhos. Exame sistêmico revelou cobre sérico elevado, ceruloplasmina sérica normal, e proteína total normal. Eletroforese de proteínas séricas demonstrou um pico único na região gama (proteína M = 11 g/l). Análise citométrica de aspirado medular evidenciou uma população de células plasmáticas monoclonais de aproximadamente 2% do total de células medulares consistente com o diagnóstico de gamopatia monoclonal de significância indeterminada. Depósitos de cobre a nível da membrana de Descemet podem ser encontrados em pacientes com gamopatia monoclonal de significância indeterminada.
Subject(s)
Humans , Female , Middle Aged , Copper/analysis , Monoclonal Gammopathy of Undetermined Significance/diagnosis , Descemet Membrane/chemistry , Paraproteinemias/diagnosis , Blood Protein Electrophoresis , Copper/blood , Monoclonal Gammopathy of Undetermined Significance/blood , Descemet Membrane/metabolism , Paraproteinemias/bloodABSTRACT
Most patients with multiple myeloma have an abnormal band in the gamma region of protein electrophoresis. To correlate the clinical diagnosis with patterns of protein electrophoresis. Retrospective analysis of all protein electrophoresis or immunoglobulin quantification requested during 1992 and review of clinical charts of patients. During 1992, 553 protein electrophoresis were requested. Of these, 344 were repetitions and 209 came from patients seen for the first time. Among the latter, we found a monoclonal component in 40. Of these 40 patients, 35 had a multiple myeloma, one had a plasmocytoma and four a non-Hodgkin lymphoma. 14 patients with diagnosis of myeloma did not have a monoclonal component in protein electrophoresis. These figures resulted in a 71 percent sensitivity and 97 percent specificity for monoclonal components in the diagnosis of multiple myeloma. The monoclonal component of patients with myeloma was characterized as IgG in 29 (60 percent), IgA in 5 (10 percent) and IgM in one. A monoclonal component present in a protein electrophoresis has a high diagnostic accuracy for multiple myeloma